Search Results for "HIV"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for HIV. Results 161 to 170 of 181 total matches.
Resperate for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
:
Drugs for Non-HIV Viral Infections — July 2007
Drugs for Allergic Disorders — August 2007
Drugs ...
The FDA has approved the marketing of Resperate (InterCure), a device that helps patients breathe slowly, as an adjunct for treatment of hypertension. The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.
Lapatinib (Tykerb) for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Sep 10, 2007 (Issue 1269)
) for HIV
Influenza Vaccine 2007-2008
Pregabalin (Lyrica) for Fibromyalgia
Coming Soon in Treatment ...
Lapatinib (Tykerb - GlaxoSmithKline), an oral inhibitor of both HER-2 and epidermal growth factor receptor type 1 (EGFR-1 or ErbB-1), has been approved by the FDA for use in combination with capecitabine (Xeloda) to treat advanced or metastatic breast cancer that overexpresses HER-2 in patients who have received prior therapy that included an anthracycline, a taxane and trastuzumab (Herceptin), an intravenous monoclonal antibody that also inhibits HER-2.
Blood Test for Tuberculosis
The Medical Letter on Drugs and Therapeutics • Oct 08, 2007 (Issue 1271)
Maraviroc (Selzentry) for HIV
Fluticasone Furoate (Veramyst) for Allergic Rhinitis
Coming Soon ...
Quantiferon - TB Gold (Cellestis) is a T-cell interferon-gamma release assay approved by the FDA as an alternative to the tuberculin skin test for diagnosis of infection with Mycobacterium tuberculosis (TB). An earlier assay (Quantiferon-TB), which is no longer commercially available, was approved by the FDA in 2001. Other interferon-gamma release assays (IGRAs) are available abroad.
Expanded Table: Some Vaccines for Travelers (online only)
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
; persons with HIV
infection; travelers at increased
risk of exposure
▶ Live-attenuated vaccine
▶ Mild ...
View the Expanded Table: Some Vaccines for Travelers
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
sexually
transmitted infections, and may increase the risk of
HIV infection.
MECHANISM OF ACTION ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Which Statin?
The Medical Letter on Drugs and Therapeutics • Apr 21, 2008 (Issue 1284)
such as itraconazole
(Sporanox), ketoconazole (Nizoral, and others), clarithromycin (Biaxin), nefazodone, and many HIV ...
Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
malignancy, HIV,
Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, congenital ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
:1066.
With increasing travel, immigration, use of immunosuppressive drugs and the spread
of HIV ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
, clarithromycin
(Biaxin), HIV protease inhibitors, verapamil (Calan, and
others) and amiodarone (Cordarone ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
:
Drugs for Non-HIV Viral Infections — July 2007
Drugs for Allergic Disorders — August 2007
Drugs ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)